New Treatment Fights Lung Cancer and Muscle Wasting at Same Time

Topic: Health

Scientists in Oregon have developed a new treatment that targets lung cancer and muscle wasting simultaneously. The treatment uses tiny particles to deliver genetic material directly to lung tumors, reducing tumor growth and promoting muscle growth.

Researchers at Oregon State University (OSU) have created an experimental treatment for lung cancer that also tackles the severe muscle loss associated with it. This condition is called cachexia.

The treatment uses lipid nanoparticles (LNPs) to carry therapeutic genetic material directly to lung tumors. LNPs are tiny particles, typically measuring between one and 100 billionths of a meter. They are made up of fatty acids and related organic compounds that include many natural oils and waxes.

In experiments using mice, the team led by Oleh Taratula and Yoon Tae Goo tested nanocarriers containing follistatin messenger RNA (mRNA). The nanoparticles accumulated in lung tumors, where the mRNA instructed cells to produce follistatin. Follistatin is a protein that can help suppress tumor growth while also supporting muscle tissue.

The researchers designed their treatment to address both problems at once by using follistatin mRNA, which has effects related to both tumor suppression and muscle growth. They found that their approach achieved an approximately 2.5-fold greater reduction in tumor burden compared to conventional LNPs.

Why It Matters

Lung cancer is a major health concern in India, with over 150,000 new cases diagnosed every year. A treatment that can target both lung cancer and muscle wasting could greatly improve patient outcomes and quality of life.

Key Facts

• Researchers at Oregon State University have developed an experimental treatment for lung cancer that also tackles muscle wasting.
• The treatment uses lipid nanoparticles to carry therapeutic genetic material directly to lung tumors.
• Follistatin mRNA is used to instruct cells to produce a protein that can help suppress tumor growth and promote muscle growth.
• The treatment has shown promise in preclinical studies, with an approximately 2.5-fold greater reduction in tumor burden compared to conventional LNPs.
• Lung cancer is the third most common cancer in the United States, with over 230,000 new cases diagnosed every year.

Key Terms

mRNA

A type of genetic material that carries instructions for making proteins.

Cachexia

A serious condition that causes severe weight and muscle loss, often associated with cancer.

Implications

Lung cancer is a major health concern in India, with over 150,000 new cases diagnosed every year. A treatment that can target both lung cancer and muscle wasting could greatly improve patient outcomes and quality of life.